Episurf Medical (NASDAQ: EPIS B) today announces that the Spanish authority AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) has approved the Episealer® knee implant for marketing and sale in Spain. The approval follows a review process and Episurf Medical will now continue the process of establishment on the Spanish market.
“We are happy for this approval which follows our strategy. Spain is a market of significant size with a large number of knee replacements annually. Knee osteoarthritis is a global disease and the global markets are homogenous when it comes to prevalence. We look forward to taking the next steps in Spain shortly”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CEST on 3 April 2018.